These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7506794)

  • 1. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
    Sartor O; Cooper M; Weinberger M; Headlee D; Thibault A; Tompkins A; Steinberg S; Figg WD; Linehan WM; Myers CE
    J Natl Cancer Inst; 1994 Feb; 86(3):222-7. PubMed ID: 7506794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
    Dawson NA; Cooper MR; Figg WD; Headlee DJ; Thibault A; Bergan RC; Steinberg SM; Sausville EA; Myers CE; Sartor O
    Cancer; 1995 Aug; 76(3):453-62. PubMed ID: 8625127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
    Dawson NA; Figg WD; Cooper MR; Sartor O; Bergan RC; Senderowicz AM; Steinberg SM; Tompkins A; Weinberger B; Sausville EA; Reed E; Myers CE
    J Clin Oncol; 1997 Apr; 15(4):1470-7. PubMed ID: 9193342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
    Small EJ; Srinivas S
    Cancer; 1995 Oct; 76(8):1428-34. PubMed ID: 8620419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J; Dieringer P; Logothetis CJ
    J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy.
    Labrie F; Dupont A; Bélanger A; Cusan L; Brochu M; Turina E; Pinault S; Lacourciere Y; Emond J
    Br J Urol; 1989 Jun; 63(6):634-8. PubMed ID: 2752257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
    Scher HI; Kelly WK
    J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
    Figg WD; Dawson N; Middleman MN; Brawley O; Lush RM; Senderowicz A; Steinberg SH; Tompkins A; Reed E; Sartor O
    Acta Oncol; 1996; 35(6):763-5. PubMed ID: 8938230
    [No Abstract]   [Full Text] [Related]  

  • 10. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
    Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E
    Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
    Kruit WH; Stoter G; Klijn JG
    Anticancer Drugs; 2004 Oct; 15(9):843-7. PubMed ID: 15457124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Fowler JE; Pandey P; Seaver LE; Feliz TP
    J Urol; 1995 Aug; 154(2 Pt 1):448-53. PubMed ID: 7541862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
    J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of flutamide in hormone-refractory metastatic prostate cancer.
    McLeod DG; Benson RC; Eisenberger MA; Crawford ED; Blumenstein BA; Spicer D; Spaulding JT
    Cancer; 1993 Dec; 72(12 Suppl):3870-3. PubMed ID: 8252506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone-refractory (D3) prostate cancer: refining the concept.
    Scher HI; Steineck G; Kelly WK
    Urology; 1995 Aug; 46(2):142-8. PubMed ID: 7624983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
    Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
    Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
    Longmore L; Foley JP; Rozanski TA; Higgins B; Thompson IM
    South Med J; 1998 Jun; 91(6):573-5. PubMed ID: 9634122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
    J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.